Jim Hoffman: Timely Extracorporeal NET Removal Therapy Should Be Tried on High-Risk Patients
Jim Hoffman, Technical Advisor at Cygnus Technologies, LLC, reposted from Jocelyn M. on LinkedIn:
“We very likely should be adding this simple rapid test to the ASCVD risk assessment, given the evidence of elevated NETosis induction, impaired NET clearance, and the participation of NETs in clotting abnormalities, structural fibrinolytic-resistant microthrombi, and larger vessel ischemic atheroma formation. Timely extracorporeal NET removal therapy should be tried on high-risk patients.
NETosis contributes to immunothrombosis from multiple infectious and non-infectious disease triggers, which contribute to vasculitis and compromise microcirculatory perfusion. Worse yet, impaired NETs clearance physically participates in life-threatening prothrombotic ischemic events, DVTs, PEs, MI, strokes and is a prime risk marker for DIC and circulatory collapse as previously demonstrated by Toh et al. For more research on dysregulated NETosis and CVD risk, visit here.″
Quoting Jocelyn M.’s post:
“We do need to do better and it is possible. In the US, heart attack risk is typically assessed according to a set of criteria such as an atherosclerotic cardiovascular disease (ASCVD) score, which measures factors linked to the development of cardiovascular disease. Patients are then monitored or treated if their scores exceed a certain threshold.
Researchers from the US and Canada gathered the health records of 465 people 65 years or younger who had been treated for their first heart attack between January 2020 and July 2025 at one of two US medical centers. The data included details such as medical history, blood pressure, and cholesterol levels.,
Based on the team’s analysis, two days before their heart attack, ASCVD scores would have categorized 45 percent of the patients at low or borderline risk levels. An alternative set of criteria, called a predicting risk of cardiovascular disease events (PREVENT) score, fared even worse: 61 percent of the patients would have been classified as low or borderline risk.”
Title: Nearly Half of All Heart Attacks May Be Missed by Current Screening Tools
Authors: David Nield
For more information, here.
Read full paper here.
Stay informed with Hemostasis Today.
-
Dec 17, 2025, 06:28Wolfgang Miesbach on Linus Völker’s Presentation of Caplacizumab as Frontline Therapy for iTTP
-
Dec 17, 2025, 06:11Lisa Murphy Thanks Stroke Foundation Team for An Impactful, Rewarding and Incredible Year
-
Dec 17, 2025, 06:05Emmanuel J Favaloro Shares A Study on AI and Machine Learning in Thrombosis and Hemostasis
-
Dec 17, 2025, 05:54Michael Bruckman: Fantastic to See Platelet-Inspired Nanoparticles Gaining Attention!
-
Dec 17, 2025, 04:00Peter Verhamme on Genetic Predisposition to Thromboembolism and COVID
-
Dec 16, 2025, 23:14Shrinidhi Nathany: MRD in AML – From a Test to a Treatment Decision
-
Dec 16, 2025, 22:16Wolfgang Miesbach – Targeting VEGF to Stop GI Bleeding: Systemic Bevacizumab
-
Dec 16, 2025, 17:14Piotr Czempik Honored for His Work on Cost Reduction in Blood Transfusions
-
Dec 16, 2025, 17:06Davood KHoda Amorzideh on VTE and Bleeding in Cancer